{"doi":"10.1111/dom.16077","title":"Early combination therapy with <scp>SGLT2i</scp> and <scp>GLP</scp> ‐1 <scp>RA</scp> or dual <scp>GIP</scp> / <scp>GLP</scp> ‐1 <scp>RA</scp> in type 2 diabetes","abstract":"Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-Like peptide-1 receptor agonists (GLP-1 RA) are recommended in people with type 2 diabetes (T2D) for glycaemic control and for people with high cardiovascular risk. However, current guidelines do not specifically address the role of initial early combination therapy with SGLT2i and GLP-1 RA or dual gastric inhibitory polypeptide (GIP)/GLP-1 RA, but rather sequential initiation with either in T2D. This review synthesizes the available evidence on the use of SGLT2i and GLP-1-based therapies for T2D and provides a rationale for their combination. The combination of SGLT2i with GLP-1-based therapies addresses complementary pathophysiological mechanisms and enhances efficacy in achieving target haemoglobin A1C (HbA1c) levels. SGLT2i and GLP-1 RA also have been shown to prevent complications of T2D. While both classes reduce adverse cardiorenal events, SGLT2i has a predominant effect on prevention of kidney dysfunction and heart failure, whereas GLP-1 RA has a more marked effect on the risk of atherosclerotic cardiovascular disease. Both drug classes have favourable safety profiles. Finally, weight loss with combination therapy may have disease-modifying effects that may reverse T2D progression. We propose that the combination of SGLT2i with GLP-1 RA or dual GIP/GLP-1 RA should be considered for most patients with T2D who do not have contraindications.","journal":"Diabetes Obesity and Metabolism","year":2024,"id":422746,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":26,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9534,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1217148,"name":"Inês Mariana Lourenço","orcid":"0000-0003-0752-0802","position":1,"is_corresponding":false},{"id":1217717,"name":"Gabriela Jordan","orcid":null,"position":2,"is_corresponding":false},{"id":709033,"name":"Ilya Golovaty","orcid":"0000-0002-6493-0499","position":3,"is_corresponding":false},{"id":1217149,"name":"Hugo Amador Herrera Torres","orcid":"0000-0003-3685-4043","position":4,"is_corresponding":false},{"id":443924,"name":"Tannaz Moin","orcid":"0000-0002-5035-6641","position":5,"is_corresponding":false},{"id":491641,"name":"Martin Buysschaert","orcid":"0000-0001-5477-3525","position":6,"is_corresponding":false},{"id":491639,"name":"João Sérgio Neves","orcid":"0000-0002-8173-8255","position":7,"is_corresponding":false},{"id":363950,"name":"Michael Bergman","orcid":"0000-0003-2589-2976","position":8,"is_corresponding":false},{"id":1217147,"name":"Catarina Vale","orcid":"0000-0001-9213-7490","position":0,"is_corresponding":true}],"reference_count":132,"raw_metadata":null,"created_at":"2026-07-19T01:57:51.642883Z","pmid":"39604324","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}